NCT00577122View on ClinicalTrials.gov

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Estrogen Receptor-negative Breast CancerProgesterone Receptor-negative Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

Medroxyprogesterone progesterone acetate (MPA)

1000 mg po daily

DRUG

Medroxyprogesterone with Cyclophosphamide + Methotrexate

Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week

Trial Locations (7)

27599

University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Comprehensive Cancer Center, Durham

35294

University of Alabama at Birmingham, Birmingham

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

77030

The University of Texas M. D. Anderson Cancer Center, Houston

94115

University of California, San Francisco Comprehensive Cancer Center, San Francisco

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Translational Breast Cancer Research Consortium

OTHER

lead

Indiana University

OTHER

NCT00577122 - Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter